Disc Medicine (IRON) PT Raised to $120 at BMO Capital following positive phase 3 results

October 19, 2026 10:15 AM EDT Send to a Friend
BMO Capital analyst Evan David Seigerman raised the price target on Disc Medicine (NASDAQ: IRON) to $120.00 (from $100.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login